ZVRA logo

ZVRA Zevra Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$8.76
-0.31 (-3.42%)

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily ad…

Market Cap: $521.26Mzevra.com

Price

No data yet.

Social Signal Score

46
5d
30
1 mentions
—
30d
50
3 mentions
—
60d
51
6 mentions
—
90d
52
8 mentions
—
news: 8

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 0Sell 0Strong Sell 0
Avg price target$24.25+176.8%
Low $18Median $22High $35
Current Consensus

Revenue

$37.76M
$0.00$13.22M$26.44M$39.66M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$1.25
$1.18–$1.32
2 analysts
FY2026
$1.26+1% YoY
$1.24–$1.29
4 analysts
FY2027
$0.89-29% YoY
$0.66–$1.11
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Neil F. McFarlane
Sector
Healthcare
Industry
Biotechnology
Employees
61
Beta
0.99
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
4.73
zevra.com